Impact of Indinavir on the Quality of Life in Patients with Advanced HIV Infection Treated with Zidovudine and Lamivudine

Coplan, Paul M.; Cook, John R.; Carides, George W.; Heyse, Joseph F.; Wu, Albert W.; Hammer, Scott M.; Nguyen, Bach-Yen; Meibohm, Anne R.; DiNubile, Mark J.
August 2004
Clinical Infectious Diseases;8/1/2004, Vol. 39 Issue 3, p426
Academic Journal
Objective. in AIDS Clinical Trial Group (ACTG) study 320, triple-combination antiretroviral therapy including indinavir significantly slowed progression to acquired immunodeficiency syndrome or death, compared with treatment with dual nucleoside reverse-transcriptase inhibitors (NRTIs) alone, in zidovudine-experienced patients with advanced human immunodeficiency virus (HIV) infection. We examined the impact of indinavir on quality of life in participants from this study. Methods. A total of 1156 protease inhibitor- and lamivudine-naive patients stratified by CD4 cell count (⩽ 50 and 51-200 cells/mm³) were randomized to receive zidovudine (or stavudine) and lamivudine, with or without indinavir. Health-related quality of life was measured using the ACTG QoL6O1-602 questionnaire, which assesses general health status measured on a visual analogue scale and 8 specific health-related domains. Quality-adjusted survival time was estimated using the visual analogue scale for general health. Results. Mean changes in general health scores after 24 weeks were +2.9 in the triple-therapy group versus -0.2 in the dual-therapy group (P = .018). By week 24, scores in all specific domains were higher with triple-drug therapy than dual-drug therapy, with statistically significant differences in role function, energy, and pain scores. Benefits of triple-drug therapy were largely confined to patients with CD4 cell counts of ⩽50 cells/mm³. Quality-adjusted survival time did not differ significantly between the 2 treatment groups. Conclusions. Triple-drug therapy with indinavir and 2 NRTIs resulted in a significant improvement in general health status after 24 weeks, especially in patients with low CD4 cell counts. Patients receiving triple-drug therapy also had significantly better role function, energy, and pain scores than did patients treated with dual-drug therapy.


Related Articles

  • The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. Anis, A.H.; Guh, D.; Hogg, R.S.; Wang, X-H.; Yip, B.; Craib, K.J.P.; O'Shaughnessy, M.V.; Schechter, M.T.; Montaner, J.S.G.; Craib, K J; Montaner, J S // PharmacoEconomics;2000, Vol. 18 Issue 4, p393 

    Objective: To estimate survival, the number of life-years gained and cost effectiveness of antiretroviral therapy (ART) regimens, denoted as ERA-I [zidovudine + (didanosine or zalcitabine)]; ERA-II [stavudine + (didanosine or zalcitabine) or lamivudine + (zidovudine or didanosine or...

  • Predictors of Virological Outcome and Safety in Primary HIV Type 1—Infected Patients Initiating Quadruple Antiretroviral Therapy: QUEST GW PROB3005. Hoen, Bruno; Cooper, David A.; Lampe, Fiona C.; Perrin, Luc; Clumeck, Nathan; Phillips, Andrew N.; Goh, Li-Ean; Lindback, Stefan; Sereni, Daniel; Gazzard, Brian; Montaner, Julio; Stellbrink, Hans-Jurgen; Lazzarin, Adriano; Ponscarme, Diane; Staszewski, Shlomo; Mathiesen, Lars; Smith, Don; Finlayson, Robert; Weber, Rainer; Wegmann, Laurence // Clinical Infectious Diseases;8/1/2007, Vol. 45 Issue 3, p381 

    Background. Initiation of antiretroviral therapy during primary human immunodeficiency virus (HIV)-1 infection may confer long-term benefit. Methods. After initiation of zidovudine, lamivudine, abacavir, and amprenavir therapy in patients in the QUEST cohort, predictors of virological outcome,...

  • Effect of Maintaining Highly Active Antiretroviral Therapy on AIDS Events among Patients with Late-Stage HIV Infection and Inadequate Response to Therapy. Gandhi, Tejal; Wei Wei; Amin, Kamal; Kazanjian, Powel // Clinical Infectious Diseases;3/15/2006, Vol. 42 Issue 6, p878 

    Background. We evaluated the effect of maintaining highly active antiretroviral therapy (HAART) on the development of new acquired immunodeficiency syndrome (AIDS)-related events in patients with late-stage human immunodeficiency virus (HIV) infection who had suboptimal CD4+ cell count and viral...

  • Living in rural New England amplifies the risk of depression in patients with HIV. Sheth, Siddharth H.; Jensen, Paul T.; Lahey, Timothy // BMC Infectious Diseases;2009, Vol. 9 Issue 1, Special section p1 

    Background: The importance of depression as a complication of HIV infection is increasingly understood, and people living in rural areas are at increased risk for depression. However, it is not known whether living in rural areas amplifies the risk of depression in patients with HIV. Methods: We...

  • Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) Trials. Raffi, François; Katlama, Christine; Saag, Michael; Wilkinson, Martin; Chung, Jain; Smiley, Lynn; Salgo, Miklos // Clinical Infectious Diseases;3/15/2006, Vol. 42 Issue 6, p870 

    Background. Early virological response to antiretroviral therapy is predictive of long-term treatment outcome in therapy-naive patients. In treatment-experienced patients, such correlations are less well defined, because initial responses may be less pronounced and transient because of...

  • Hope and hype.  // Network Magazine of the Canadian Women's Health Network;Winter1998/1999, Vol. 2 Issue 1, p3 

    Relates how the author decided to go on combination therapy to combat HIV-related symptoms. Author's initial refusal to take any AIDS drugs; Details of how the author reached the decision to try a combination of AIDS drugs; Author's daily medication routine; Effects of the combination therapy.

  • Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study. Sierra-Madero, Juan; Di Perri, Giovanni; Wood, Robin; Saag, Michael; Frank, Ian; Craig, Charles; Burnside, Robert; McCracken, Jennifer; Pontani, Dennis; Goodrich, James; Heera, Jayvant; Mayer, Howard // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p125 

    Background: The MERIT study evaluated maraviroc versus efavirenz, both with zidovudine/lamivudine, in treatment-naïve patients with CCR5-tropic (R5) HIV-1. Post hoc analyses previously assessed week 48 outcomes in patients rescreened with R5 virus by a more sensitive tropism assay. Methods:...

  • Keeping HIV at Bay. Juarez, Vanessa // Newsweek;Summer2005 Special Edition, Vol. 145 Issue 26A, p31 

    Reports on the efforts of HIV-positive patients to treat their disease. Ability of the virus to adapt to medications used; Concerns that patients are exhausting their options for antiretroviral treatment; How drug cocktails, including AZT, work when people adhere to them perfectly and use them...

  • Possible Mechanism of Toxicity of Zidovudine by Induction of Apoptosis of CD4+ and CD8+ T-Cells in Vivo. Benveniste, O.; Estaquier, J.; Lelièvre, J. D.; Vildé, J. L.; Ameisen, J. C.; Leport, C. // European Journal of Clinical Microbiology & Infectious Diseases;Dec2001, Vol. 20 Issue 12, p896 

    Some HIV-infected patients have a discordant response to highly active antiretroviral therapy with a low virus load and an incomplete restoration of CD4+ T-cell counts. Zidovudine may limit CD4+ restoration by a hematotoxic mechanism. Apoptosis and T-cell counts were assessed in two patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics